

10/569315

AP20 Rec'd PCT/PTO 21 FEB 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (RO/US)

Applicant : Housey Pharmaceuticals
International Appln. No. : PCT/US2005/18412
International Filing Date : 23 May 2005
For : Therameutin Modulators

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Attn.: Authorized Officer James O. Wilson

ARTICLE 34 AMENDMENT

Sir:

Accompanying the Demand for International Preliminary Examination being filed concurrently herewith is an Amendment under Article 34 for entry in the above-identified International Application.

IN THE SPECIFICATION:

On page 8, please delete the paragraph starting with "2. Theramuteins" and replace with the following paragraph:

--2. Theramuteins of the invention that are of particular interest are those involved in regulatory function, such as enzymes, protein kinases, tyrosine kinases, receptor tyrosine kinases, serine threonine protein kinases, dual specificity protein kinases, proteases, matrix metalloproteinases, phosphatases, cell cycle control proteins, docking proteins such as the IRS family members, cell-surface receptors, G-proteins, ion channels, DNA- and RNA-binding proteins, polymerases, and the like. No limitation is intended on the type of theramutein that may be used in the invention. At the present time, three theramuteins are known: BCR-ABL, c-Kit, and EGFR. --

On page 9, please delete paragraph [0019] and replace with the following paragraph:

-- Figure 3 shows various determinations of the specificity gap by comparing the effects of various compounds identified in the screen in terms of

SV 320245270 US